Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
about
Parainfluenza virusesRecombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primatesProgress in the development of human parainfluenza virus vaccinesViral etiology of severe pneumonia among Kenyan infants and children.Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneImmunization strategies for the prevention of pneumovirus infections.Recovery of avian metapneumovirus subgroup C from cDNA: cross-recognition of avian and human metapneumovirus support proteins.Nonsegmented negative-strand viruses as vaccine vectors.Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA.Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.Carriers for the delivery of a vaccine against respiratory syncytial virus.Need for a safe vaccine against respiratory syncytial virus infection.Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BLive vaccines for human metapneumovirus designed by reverse genetics.Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignRespiratory syncytial virus: current progress in vaccine development.RNA-based viral vectors.Animal models of respiratory syncytial virus infection.Vaccine development for respiratory syncytial virus.Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Inhibition of respiratory viruses by nasally administered siRNA.Respiratory syncytial virus vaccine developmentProgress in respiratory virus vaccine development
P2860
Q24682952-C3FAF195-D2EB-4ADD-94B7-1CF408322084Q34092801-3953FC29-EF01-4DFB-B0F9-EBB4FF3E6B62Q34209872-43B9DBE8-467E-4C92-AE33-9AC3796903ABQ34262582-86EB0F48-E1CF-46C4-AB8B-4971B788334DQ34328895-51D90F15-B3E3-459E-9527-4C8816CE1989Q34615678-50BF33BB-9664-4FE0-ABF6-B274DEB3A7E4Q34651310-A011FB02-9ECD-46AD-9670-FD64DD2B36F4Q35139219-C0480C53-5BF0-4134-9B76-DE669103F911Q35705123-36545201-2879-49B6-8048-8778DEE34F5EQ35973617-0E02E130-C078-4BA4-B564-7B91E05A869CQ36086315-B6E5C4EA-2B3B-4402-A083-912076AE4BDEQ36194078-3A0467A5-4545-4E8D-AE75-F6ED7EF3CFE7Q36266896-CC68D7EE-FBE5-47C3-89A8-70CD4813FE2DQ36453608-9D66021E-FC4C-4907-9FB4-042CA7AFC69DQ36689031-07C58B82-EB0F-4C7F-A972-5CC93739C3DCQ36961947-C0E351EC-2845-4AA0-8E34-C261C4D5346CQ37342874-94EFE5D2-FE4B-4F25-B447-3C793D887C3BQ37347267-8377BE6A-C4E2-47B1-A6B2-9B3FD728720BQ37348134-D5BBB719-BE83-4237-80EC-2E8D73A22BAAQ37713874-3F8EB35B-5D5E-4E08-A995-592DDAA0B20DQ37729137-BCCB22BE-A0C3-4A04-BBE4-78F48D841A7CQ38079432-E3D7FED4-57F8-4396-A0B8-6DA8CCFFFB10Q38266413-13EDA4F5-6EF3-47A8-AAE7-F179A8900405Q39026362-3B1B3E06-74BE-41E9-BD15-7224630A0626Q39318444-C5D5251F-65F8-4900-9E0F-D38A7DEA1F1CQ39997643-43DA0173-1E7E-4846-A3BA-3C88A80698CEQ40187606-8ADB8A55-B89A-4193-8226-3E6036CEAA7FQ40312271-1CA4707C-2614-4704-9C53-942B2EB5228CQ40796422-1BCEC83A-2B49-4CCC-B61E-B5C36D6DC10FQ47555408-79BF8427-EAEB-497F-84EC-C4BE0E1B6D10Q47874231-7359A896-6483-4422-989F-CA78CA111824Q56893551-9BCF1028-6421-4DD7-B1C4-20B4A4E04ABBQ56894869-DEF4719D-FD90-4CA9-8487-729028872101
P2860
Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@ast
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@en
type
label
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@ast
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@en
prefLabel
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@ast
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@en
P2093
P2860
P1433
P1476
Recombinant bovine/human parai ...... ization against RSV and HPIV3.
@en
P2093
A C Schmidt
B R Murphy
J M McAuliffe
P L Collins
P2860
P304
P356
10.1128/JVI.75.10.4594-4603.2001
P577
2001-05-01T00:00:00Z